Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New Non-Invasive lung nodule marking method tested in small trial

NCT ID NCT07257549

Disease control Sponsor: The First Affiliated Hospital of Guangzhou Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Sep 11, 2026 · Updated 3 times

Summary

This pilot study tested a new, non-invasive way to locate multiple small lung nodules (under 20 mm) before surgery, comparing it to the standard CT-guided needle method. Forty people with early-stage lung cancer took part. The goal was to see if the new method could help surgeons successfully remove all targeted nodules with clear margins.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
real-time non-invasive localization (procedure)
What this could lead to
If successful, this technique could make lung nodule surgery more precise and less invasive, potentially reducing complications and improving outcomes for patients with early-stage lung cancer.
What could go wrong
This is a small pilot study with only 40 participants, so results may not apply to all patients. The new method may not be as accurate as the standard approach, and technical challenges could limit its use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

120 people

The number who actually took part.

Started

Jul 2024

Finished

Jul 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. the maximum diameter of the lesion on CT did not exceed 20 mm; 2. at least two pulmonary nodules identified; 3. pulmonary nodules showed pure ground-glass opacity (GGO) or mixed GGO on imaging; 4. the outer edge of nodules located between 5-20 mm from the nearest pleural surface. Exclusion Criteria: 1. nodule location obstructed by the scapula, precluding needle access; 2. proximity of the nodule to major blood vessels, defined as within 2 cm; 3. requirement for localization of multiple pulmonary nodules.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lung cancer (NSCLC) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

lung cancer lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lung cancer (NSCLC)

Contacts and locations

Locations

  • The First Affiliated of Guangzhou Medical University

    Guangzhou, Guangdong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.